Implementation of TRIPS and Access to Medicines for HIV after January 2016: Strategies and Options for Least Developed Countries
This document seeks to analyse how LDCs have utilized the 2016 extension to facilitate the production and access to HIV and other medicines for their populations; discuss what can be done to maximize the opportunities provided by the current extensions; describe the potential implications of LDCs having to implement the TRIPS Agreement with respect to pharmaceuticals and test data protection; fill the gaps in the understanding of the process for further extension of the transition period for pharmaceutical products; and provide recommendations on how LDCs should proceed to seek further extensions.
Related feature storiesFirst Lady of Kenya runs half marathon to end new HIV infections among children and improve the lives of mothers
11 March 2014New advances in HIV research and development
10 March 2014Better development outcomes through participation: The role of women, the young people and civil society in the post-2015 debate
10 March 2014